TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shuttle Pharmaceuticals Holdings, Inc. ( (SHPH) ) has provided an announcement.
On October 15, 2025, Shuttle Pharmaceuticals Holdings, Inc. received a termination notice from Theradex Systems, Inc. regarding their master agreement, leading to a settlement where Shuttle Pharmaceuticals will pay $300,000 to Theradex to settle outstanding liabilities. Consequently, Shuttle Pharmaceuticals has decided to discontinue its clinical trials of Ropidoxuridine, expecting to incur additional expenses related to trial closeout activities, with most charges anticipated in the fourth quarter of 2025.
Spark’s Take on SHPH Stock
According to Spark, TipRanks’ AI Analyst, SHPH is a Underperform.
Shuttle Pharmaceuticals Holdings, Inc. faces significant financial challenges with no revenue and ongoing cash burn. Technical indicators show bearish trends, and valuation metrics highlight the company’s unprofitability. While recent corporate activities offer potential strategic benefits, they also add financial strain and governance complexities, leading to an overall low stock score.
To see Spark’s full report on SHPH stock, click here.
More about Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc. operates in the pharmaceutical industry, focusing on the development of drugs and therapies. The company is involved in clinical trials and research, particularly in the area of cancer treatment.
Average Trading Volume: 233,292
Technical Sentiment Signal: Sell
Current Market Cap: $3.17M
For a thorough assessment of SHPH stock, go to TipRanks’ Stock Analysis page.